Novel Products to Simplify In-Clinic DMT Administration

August 24, 2020 Articles 7:21 pm

Viridia, a new company, is a wholly-owned subsidiary of ATAI Life Sciences AG, a global biotech platform. The company will generate multiple DMT products “based on alternative routes to intravenous administration.” This is a common method for giving DMT. Ultimately, Viridia will leverage ATAI Life Science’s drug development expertise.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit

JOIN THE ATAI #INSIGHTNETWORK

Sign up to receive the latest news on atai.